DA-5216 is under clinical development by Dong-A ST and currently in Phase I for Idiopathic (Essential) Hypertension. According to GlobalData, Phase I drugs for Idiopathic (Essential) Hypertension does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the DA-5216 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DA-5216 overview
DA-5216 is under development for the treatment of essential hypertension.
Dong-A ST overview
Dong-A ST is a pharmaceutical company. It manufactures and sells ethical drugs, medical devices, and diagnostic tests in South Korea. The company offers ethical drugs including gonadopin injection, dulastin progression-free survival, mainta injection, monotaxel injection, motilitone tablet, suganon tablet, sugamet XR tablet, closerin capsule, growtropin II and leucostim. Dong-A ST also offers diagnostic solutions for identification of Malaria, dengue combo, anti-HBs, HBsAg, Hepatitis C, HIV 1/2, Syphilis and Ebola Ag diseases. The company is also engaged in the research to develop new drugs. Dong-A ST is headquartered in Seoul, South Korea.
For a complete picture of DA-5216’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
